Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Symlin pramlintide: Phase IIIb; NDA under review

In a U.S. Phase IIIb dose-titration study in 296 patients receiving daily insulin injections or insulin pump therapy, Symlin plus insulin was non-inferior to insulin

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE